Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy

摘要

More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations. Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.